Genprex entered a new Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN biomarkers for Reqorsa gene therapy patient response, while furnishing an investor presentation under Regulation FD.
Key takeaways
Entered new SRA with UT MD Anderson on April 21, 2026, to study TROP2 and PTEN biomarkers predicting Reqorsa response in NSCLC and SCLC.
TROP2 and PTEN identified in preclinical studies as potential biomarkers to refine patient selection for Acclaim-1 and Acclaim-3 trials.
Acclaim-1 Phase 2a enrolling after Phase 1 showed no DLTs, prolonged PFS in three patients, and one partial response lasting 42 months.
Acclaim-3 Phase 2 enrolling after Phase 1 showed no DLTs and one unconfirmed partial response after 24 cycles over 18 months.
Investor presentation (Exhibit 99.1) available on www.genprex.com for investor meetings starting April 21, 2026.